Phase 1 study to determine the metabolism and clearance of baxdrostat

Exclusion Criteria

• - Significant history or clinical manifestation of any diseases as determined by the
• investigator
• - Prolonged QTcF (>450 msec)
• - Confirmed (eg, 2 consecutive measurements) systolic BP >140 or <90 mmHg,
• diastolic BP >90 or <50 mmHg, and pulse rate >100 or <45 beats per minute (bpm).
• - Postural tachycardia (ie, >30 bpm upon standing) or orthostatic hypotension (ie, a fall
• in systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg upon standing).
• - Serum potassium >upper limit of normal (5.3 mmol/L; ULN) of the reference range
• and serum sodium
• - Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values
• >1.2 × ULN.
• - A known history of porphyria, myopathy, or active liver disease
• - Use of any prescription medications
• - Corticosteroid use (systemic or extensive topical use) within 3 months prior
• to dosing
• - Subjects who have participated in more than 3 radiolabeled drug studies in the last
• 12 months